250,000 Shares in Drugs Made In America Acquisition II Corp. $DMII Acquired by SkyView Investment Advisors LLC

SkyView Investment Advisors LLC acquired a new stake in Drugs Made In America Acquisition II Corp. (NASDAQ:DMII) in the second quarter, HoldingsChannel.com reports. The firm acquired 250,000 shares of the company’s stock, valued at approximately $2,515,000. Drugs Made In America Acquisition II makes up about 2.1% of SkyView Investment Advisors LLC’s investment portfolio, making the stock its 12th largest position.

Several other large investors have also modified their holdings of DMII. Gabelli Funds LLC purchased a new position in shares of Drugs Made In America Acquisition II during the first quarter worth approximately $1,609,000. GABELLI & Co INVESTMENT ADVISERS INC. purchased a new stake in Drugs Made In America Acquisition II in the 1st quarter valued at $1,790,000. Clear Street Group Inc. acquired a new stake in Drugs Made In America Acquisition II during the 4th quarter worth $1,797,000. Mint Tower Capital Management B.V. acquired a new position in Drugs Made In America Acquisition II in the fourth quarter valued at $2,475,000. Finally, Periscope Capital Inc. purchased a new stake in shares of Drugs Made In America Acquisition II in the fourth quarter valued at about $2,628,000.

Drugs Made In America Acquisition II Stock Up 0.1%

Shares of NASDAQ DMII opened at $10.17 on Tuesday. The stock has a fifty day moving average price of $10.12 and a 200 day moving average price of $10.06. Drugs Made In America Acquisition II Corp. has a 1-year low of $9.86 and a 1-year high of $10.21.

Drugs Made In America Acquisition II (NASDAQ:DMII) last announced its quarterly earnings data on Friday, August 14th. The company reported $0.07 earnings per share (EPS) for the quarter.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings upgraded shares of Drugs Made In America Acquisition II from a “sell (e)” rating to a “sell (d-)” rating in a research note on Tuesday, September 1st. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company presently has an average rating of “Sell”.

Drugs Made In America Acquisition II Profile

Drugs Made In America Acquisition II (NASDAQ:DMII) is a special purpose acquisition company (SPAC) formed to raise capital through a public listing for the purpose of effecting a business combination. As a blank‑check vehicle, the company itself does not operate a traditional commercial business; instead, it seeks to identify, negotiate and complete an acquisition, merger, share exchange, asset purchase or similar business transaction with one or more target companies.

The stated investment focus reflected in the company’s name indicates an emphasis on the pharmaceutical and life sciences sector, with a particular interest in domestic drug manufacturing, supply‑chain resiliency and related healthcare operations in the United States.